Day: January 12, 2018

A leader in targeted epigenetic drug discovery and development for improved therapeutic outcomes.

‘This program increases our broadening pipeline of targeted epigenetic medicines and is another example of the wide array of human disease indications that selective HDAC inhibitors hold guarantee.’ Related StoriesSingle gene variation may impact obesity in kids, adultsScalable production of gene therapy vectors: an interview with Frank UbagsPerisylvian polymicrogyria gene found The induction of HbF can be an established therapeutic strategy for SCD and could potentially also be a highly effective therapeutic strategy for bT. Previous studies suggested that non-specific HDAC inhibitors were effective in inducing HbF, nevertheless, their advancement has been delayed because of concerns over variable efficacy and off-target side-effects. Acetylon scientific founders James E. Bradner, MD, and Ralph Mazitschek, Ph.D., of Harvard Medical School first demonstrated the prospect of selective HDAC1/2 inhibition in inducing HbF . Read More

AB SCIEX launches 3200MD CE-IVDD series in European countries for in vitro diagnostic use AB SCIEX.

AB SCIEX launches 3200MD CE-IVDD series in European countries for in vitro diagnostic use AB SCIEX, a global leader in analytical systems, today announced the start of the 3200MD CE-IVDD series for general in vitro diagnostic make use of in Europe. Now, we are bringing these benefits to Europe in a manner that will simplify and accelerate adoption of the powerful technology. Related StoriesNew data evaluation platform reveals main flaw in GC-MS processNew research from TSRI and Salk points to reason behind debilitating nerve diseaseEfficient respiratory medical diagnosis solution ‘We are focused on interacting with the medical, technical and compliance requires of clinical diagnostic laboratories and hospitals,’ stated Rainer Blair, President of AB SCIEX sulbutiamine choline . Read More